BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32107870)

  • 1. Salvage surgery for advanced non-small cell lung cancer after targeted therapy: A case series.
    Song W; Di S; Liu J; Fan B; Zhao J; Zhou S; Chen S; Dong H; Yue C; Gong T
    Thorac Cancer; 2020 Apr; 11(4):1061-1067. PubMed ID: 32107870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage surgery following downstaging of advanced non-small cell lung cancer by targeted therapy.
    Li K; Cao X; Ai B; Xiao H; Huang Q; Zhang Z; Chu Q; Zhang L; Dai X; Liao Y
    Thorac Cancer; 2021 Aug; 12(15):2161-2169. PubMed ID: 34128318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
    Germonpré P; Van den Wyngaert T
    PLoS One; 2019; 14(4):e0215135. PubMed ID: 30973926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
    Dickhoff C; Dahele M; Paul MA; van de Ven PM; de Langen AJ; Senan S; Smit EF; Hartemink KJ
    Lung Cancer; 2016 Apr; 94():108-13. PubMed ID: 26973215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer?
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    J Cardiothorac Surg; 2016 Jan; 11():9. PubMed ID: 26781697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
    Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
    Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer.
    Seol KH; Lee JE; Cho JY; Lee DH; Seok Y; Kang MK
    Thorac Cancer; 2017 Nov; 8(6):620-629. PubMed ID: 28906073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
    Yue-Yun C; Ye H; Yang F; Qing L; Pan-Pan L; Zhen-Yu D
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2415-2420. PubMed ID: 31450915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage surgery for advanced non-small cell lung cancer following previous immunotherapy: a retrospective study.
    Higuchi M; Inomata S; Yamaguchi H; Saito T; Suzuki H
    J Cardiothorac Surg; 2023 Jul; 18(1):235. PubMed ID: 37475037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.
    Kowalchuk RO; Waters MR; Richardson M; Spencer K; Larner JM; Kersh CR
    Thorac Cancer; 2020 Jul; 11(7):2005-2013. PubMed ID: 32469465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
    Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
    Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
    She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
    Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.